Showing 2321-2330 of 4063 results for "".
- AstraZeneca Says COVID-19 Vaccine Candidate Shows 70% Efficacyhttps://modernod.com/news/astrazeneca-says-covid-19-vaccine-candidate-shows-70-efficacy/2478588/AstraZeneca announced that a combined interim analysis of late-stage studies showed that the COVID-19 candidate vaccine AZD1222 had an average efficacy of 70%, increasing to 90% for a regimen that included initial immunization with a half dose. The pooled data come from the COV002 phase 2/3 trial
- Kala Pharmaceuticals Provides Update on Launch Plans for Eysuvis for the Treatment of Dry Eye Diseasehttps://modernod.com/news/kala-pharmaceuticals-provides-update-on-launch-plans-for-eysuvis-for-the-treatment-of-dry-eye-disease/2478550/Kala Pharmaceuticals provided an update on its plans to launch Eysuvis (loteprednol etabonate ophthalmic suspension) 0.25% for the short-term (up to 2 weeks) treatment of the signs and symptoms of dry eye disease. “We continue to make significant progress on our plans to launch Eysuvis and
- Oyster Point Pharma Announces Clinical Data Presentations on OC-01 Nasal Spray for Dry Eye Disease at AAO Virtualhttps://modernod.com/news/oyster-point-pharma-announces-clinical-data-presentations-on-oc-01-nasal-spray-for-dry-eye-disease-at-aao-virtual/2478548/Oyster Point Pharma announced new data from its phase 2 IMPERIAL clinical trial evaluating OC-01 (varenicline) nasal spray in the treatment of the signs and symptoms of dry eye disease in adults at the AAO 2020 Virtual Annual Meeting, being held on November 13-15. A single administration o
- AstraZeneca’s Calquence Fails to Help Patients Hospitalized With COVID-19 Respiratory Symptomshttps://modernod.com/news/astrazenecas-calquence-fails-to-help-patients-hospitalized-with-covid-19-respiratory-symptoms/2478544/AstraZeneca announced that the phase 2 CALAVI studies investigating the addition of Calquence (acalabrutinib) to best supportive care (BSC) in patients hospitalized with respiratory symptoms of COVID-19 failed to meet their primary efficacy endpoint. Results showed that the BTK inhibitor did not
- Russia Says COVID-19 Vaccine Sputnik V 92% Effective in Late-Stage Studyhttps://modernod.com/news/russia-says-covid-19-vaccine-sputnik-v-92-effective-in-late-stage-study/2478524/Interim results from a phase 3 study of the Gamaleya Institute’s COVID-19 vaccine Sputnik V suggest that it had an efficacy rate of 92% after the second dose, the Russian Direct Investment Fund (RDIF) announced Wednesday. The data come after 20 confirmed cases of coronavirus were recorded 2
- Last Patient, Last Visit Completed in RegeneRx Phase 3 Dry Eye Clinical Trialhttps://modernod.com/news/last-patient-last-visit-completed-in-regenerx-phase-3-dry-eye-clinical-trial/2478508/RegeneRx Biopharmaceuticals announced that the final patient in its 700 subject, ARISE-3 phase 3 clinical trial for dry eye syndrome has completed treatment and follow-up. ARISE-3 is designed to assess the safety and efficacy of 0.1% RGN-259 eye drops compared to placebo after 2 weeks of
- Early Phase 3 Data Show Pfizer, BioNTech’s COVID-19 Vaccine Over 90% Effectivehttps://modernod.com/news/early-phase-3-data-show-pfizer-biontechs-covid-19-vaccine-over-90-effective/2478507/Results from the first interim analysis of a phase 3 study of Pfizer and BioNTech’s BNT162b2 showed that the experimental mRNA-based vaccine candidate was more than 90% effective in preventing COVID-19 in participants without evidence of prior SARS-CoV-2 infection, the companies announced M
- Aurinia Pharmaceuticals’ Dry Eye Drug Candidate Does Not Meet Primary Endpointhttps://modernod.com/news/aurinia-announces-outcome-of-audrey-clinical-trial-in-dry-eye-syndrome/2478487/Aurinia Pharmaceuticals announced topline data from the phase 2/3 AUDREY clinical study evaluating voclosporin ophthalmic solution (VOS) for the potential treatment of dry eye syndrome (DES). The trial did not achieve statistical significance on its primary endpoint of a 10 mm or greater improvem
- Allergan Announces Positive Phase 3 Topline Results for Investigational Eye Drop for the Treatment of Presbyopiahttps://modernod.com/news/allergan-announces-positive-phase-3-topline-results-for-investigational-eye-drop-for-the-treatment-of-presbyopia/2478467/Allergan announced the phase 3 GEMINI 1 and 2 clinical trials evaluating the efficacy, safety, and tolerability of investigational AGN-190584 (pilocarpine 1.25%) ophthalmic solution for the treatment of symptoms associated with presbyopia, met their primary efficacy endpoint. In GEMINI 1,
- Kala Pharmaceuticals Receives FDA Approval of Dry Eye Disease Treatment Eysuvishttps://modernod.com/news/kala-pharmaceuticals-announces-fda-approval-of-dry-eye-disease-treatment-eysuvis/2478460/The FDA on Tuesday approved Kala Pharmaceuticals’ Eysuvis (loteprednol etabonate ophthalmic suspension 0.25%), making it the first ocular corticosteroid for the treatment of dry eye disease and the first drug approved specifically for the short-term (up to 2 weeks) treatment of the signs an